Barda and COVID: Innovations in Inhalational Delivery for Flu and COVID Vaccines
Barda and COVID Vaccine Innovations
Barda's initiative to combat COVID and influenza revolves around the FastX program, a pivotal project at Emory University. Under Dr. Harlan Weisman’s leadership, the emphasis is on advancing inhalational delivery methods to ensure efficient vaccine deployment.
Collaborations for Advancement
The collaboration with TFF Pharmaceuticals utilizes thin film freezing (TFF) technology to improve the viability and acceptability of mRNA vaccines against respiratory viruses.
- Key Partnerships: TFF Pharmaceuticals and Emory University
- Leadership: Dr. Harlan Weisman and Philip J. Santangelo
- Focus Areas: Inhalational delivery and vaccine efficiency
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.